← Back to Analyst Consensus 
EVMN Buy
Evommune, Inc.
Current Price —
Implied Upside —
Analysts 18
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 12, 2026 | UBS | initiate | — → Neutral | — | 54% |
| Sep 9, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Sep 9, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Sep 9, 2026 | HC Wainwright & Co. | reiterate | Neutral → Neutral | — | 44% |
| Aug 26, 2026 | Needham | initiate | — → Buy | — | 50% |
| Aug 7, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Aug 3, 2026 | HC Wainwright & Co. | reiterate | Neutral → Neutral | — | 44% |
| Jun 30, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Jun 30, 2026 | HC Wainwright & Co. | downgrade | Buy → Neutral | — | 44% |
| Jun 29, 2026 | William Blair | downgrade | Outperform → Market Perform | — | 48% |
| May 26, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 11, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Apr 10, 2026 | RBC Capital | reiterate | Outperform → Outperform | — | 55% |
| Mar 18, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 18, 2026 | Clear Street | initiate | — → Buy | — | 48% |
| Feb 10, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $65 | 44% |
| Jan 22, 2026 | Oppenheimer | initiate | — → Outperform | $42 | 52% |
| Jan 8, 2026 | Raymond James | initiate | — → Strong Buy | $40 | 54% |
| Jan 6, 2026 | HC Wainwright & Co. | initiate | — → Buy | $35 | 44% |
| Dec 1, 2025 | William Blair | initiate | — → Outperform | $0 | 48% |
| Dec 1, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $0 | 50% |
| Dec 1, 2025 | Morgan Stanley | initiate | — → Overweight | $36 | 54% |
| Dec 1, 2025 | Leerink Partners | initiate | — → Outperform | $42 | 51% |
| Dec 1, 2025 | Evercore ISI Group | initiate | — → Outperform | $40 | 58% |
Price Target Trend
Apr 17, 2026 Oct 27, 2026
EPS Estimates
+1y —
0q —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days